Quick Answer
ADIAL PHARMACEUTICALS, INC. reported Net Income of -$7.98 million for fiscal year 2025.
ADIAL PHARMACEUTICALS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$7.98M +39.6% |
-$13.20M -157.6% |
-$5.12M +59.8% |
-$12.73M +34.5% |
-$19.42M -78.3% |
-$10.89M -26.8% |
| Diluted EPS | -$11.93 +82.5% |
-$68.01 -1789.2% |
-$3.60 +71.7% |
-$12.71 -1122.1% |
-$1.04 | — |
| Total Assets | $6.67M +32.3% |
$5.04M +6.5% |
$4.74M -17.4% |
$5.73M -23.3% |
$7.47M +36.1% |
$5.49M -28.5% |
| Cash and Equivalents | $5.88M +56.8% |
$3.75M +32.7% |
$2.83M -29.4% |
$4.00M -34.0% |
$6.06M +37.7% |
$4.40M -35.1% |
| Stockholders Equity | $5.28M +29.7% |
$4.07M -0.4% |
$4.08M +24.6% |
$3.28M -6.6% |
$3.51M -12.0% |
$3.99M -44.2% |
| R&D Expense | $2.62M -18.9% |
$3.23M +154.9% |
$1.27M -35.0% |
$1.95M -76.8% |
$8.40M +43.4% |
$5.85M +47.6% |
| Operating Income | -$7.80M +5.9% |
-$8.28M -20.3% |
-$6.89M +36.6% |
-$10.86M +43.7% |
-$19.29M -76.5% |
-$10.93M -32.5% |
| Shares Outstanding | 1.11M +329.2% |
258,826 -84.4% |
1.66M +55.8% |
1.07M -94.9% |
20.95M +45.5% |
14.39M +38.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$1.79M | +18.2% | +8.4% |
| Diluted EPS | September 30, 2025 | -$0.08 | +78.9% | +55.6% |
| Total Assets | September 30, 2025 | $5.66M | -15.7% | -16.8% |
| Cash and Equivalents | September 30, 2025 | $4.61M | -11.5% | -22.1% |
| Stockholders Equity | September 30, 2025 | $4.51M | -23.4% | -19.4% |
| R&D Expense | September 30, 2025 | $521.1K | -49.5% | -28.8% |
| Operating Income | September 30, 2025 | -$1.76M | +20.2% | +6.3% |
| Shares Outstanding | September 30, 2025 | 23.84M | +272.1% | +10.7% |
- ADIAL PHARMACEUTICALS, INC. reported Net Income of -$7.98 million for fiscal year 2025.
- ADIAL PHARMACEUTICALS, INC. showed an increase of +39.6% in Net Income compared to the prior fiscal year.
- ADIAL PHARMACEUTICALS, INC. reported Diluted EPS of $11.93 per share (loss) for fiscal year 2025.
- ADIAL PHARMACEUTICALS, INC. showed an increase of +82.5% in Diluted EPS compared to the prior fiscal year.
- ADIAL PHARMACEUTICALS, INC. reported Total Assets of $6.67 million for fiscal year 2025.
- ADIAL PHARMACEUTICALS, INC. showed an increase of +32.3% in Total Assets compared to the prior fiscal year.
- ADIAL PHARMACEUTICALS, INC. reported Cash and Equivalents of $5.88 million for fiscal year 2025.
- ADIAL PHARMACEUTICALS, INC. showed an increase of +56.8% in Cash and Equivalents compared to the prior fiscal year.
- ADIAL PHARMACEUTICALS, INC. reported Stockholders Equity of $5.28 million for fiscal year 2025.
- ADIAL PHARMACEUTICALS, INC. showed an increase of +29.7% in Stockholders Equity compared to the prior fiscal year.
- ADIAL PHARMACEUTICALS, INC. reported R&D Expense of $2.62 million for fiscal year 2025.
- ADIAL PHARMACEUTICALS, INC. showed a decrease of -18.9% in R&D Expense compared to the prior fiscal year.
- ADIAL PHARMACEUTICALS, INC. reported Operating Income of -$7.80 million for fiscal year 2025.
- ADIAL PHARMACEUTICALS, INC. showed an increase of +5.9% in Operating Income compared to the prior fiscal year.
- ADIAL PHARMACEUTICALS, INC. reported Shares Outstanding of 1.11 million shares for fiscal year 2025.
- ADIAL PHARMACEUTICALS, INC. showed an increase of +329.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: